SCHEMBL6497776

SCHEMBL6497776

Cc1ccc(C(=O)Nc2ccc(OCCc3csc(C)n3)cc2)c(-c2ccc(Cl)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.49
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.43
TP53 P04637 3/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
F10 P00742 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CETP P11597 1/20 0.40
ANO1 Q5XXA6 1/20 0.40
GRM5 P41594 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489237 0.93 MAPT (0.46) GCGRMAPTLMNATP53TAS1R3
SCHEMBL6488351 0.91 SMN1; SMN2 (0.53) GCGRMAPTLMNATP53TAS1R3
SCHEMBL6500236 0.91 GCGR (0.49) GCGRMAPTLMNATP53TAS1R3
SCHEMBL6499318 0.87 MAPT (0.49) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL6489811 0.86 GCGR (0.51) GCGRMAPTLMNATP53F10
SCHEMBL6501410 0.86 SMN1; SMN2 (0.60) GCGRMAPTTP53SMN1; SMN2NPC1
SCHEMBL6501863 0.85 SMN1; SMN2 (0.43) GCGRMAPTLMNASMN1; SMN2NPC1
SCHEMBL6501928 0.84 SMN1; SMN2 (0.53) GCGRMAPTLMNATP53TAS1R3
SCHEMBL6501012 0.84 PPARG (0.51) GCGRTP53TAS1R3TAS1R1SMN1; SMN2
SCHEMBL6502718 0.84 MAPT (0.44) GCGRMAPTLMNATP53TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 GCGR 1784/4885MAPT 4202/4885LMNA 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.